This volume discusses in detail the diagnosis, treatment, and prognosis of liver cancer. Written by expert oncologists/pathologists in the field, it examines both standard and emerging therapies for this cancer.
This volume presents a detailed survey of imaging, multidetector-row computed t- various methodologies related to diagno- ography, helical computed tomography, sis, therapy, and prognosis of liver cancer, ultrasonography, and power Doppler ult- including colorectal liver metastases and sound, for the prognosis and assessment of biliary tract carcinomas, while the already liver cancer treatment (including HCC) and published Volumes 1, 2, 3, and 4 detail liver metastases from colorectal cancer are similar aspects of breast, lung, prostate, discussed in detail, as is the use of radiof- gastrointestinal, and colorectal cancer, quency ablation in hepatic tumors. respectively. Approximately 50% of colorectal cancer Surgical resection is the standard therapy (CRC) patients develop liver metastases for resectable liver disease, resulting in during the course of their disease, and 5-year overall survival rates of 20-40%. more than 50% of patients who die of CRC One the other hand, the median overall have liver metastases at autopsy. Regional survival of patients with unresectable liver lymph node (RLN) involvement in patients metastases does not exceed 18-20 months, with colorectal liver metastases is one with a 5-year survival rate approaching of the worst prognostic factors. Recent zero. In other words, there is virtually no studies indicate that for these patients, long-term survival. Both resectable and combined liver resection and pedicular unresectable liver cancers are discussed lymphadenectomy can be recommended, in this volume. The method of selecting when RLN metastases respond to p- patients for resection of hepatic colorectal operative chemotherapy.
Inhaltsverzeichnis
Liver Cancer. - Applications of Positron Emission Tomography in Liver Imaging: An Overview. - Localized Fibrous Tumor of the Liver: Imaging Features. - A Radial Magnetic Resonance Imaging Method for Imaging Abdominal Neoplasms. - Liver: Helical Computed Tomography and Magnetic Resonance Imaging. - Resectable Liver Cancer. - Selection of Patients for Resection of Hepatic Colorectal Metastases: 18F-Fluorodeoxyglucose/Positron Emission Tomography. - Ultrasonography During Liver Surgery. - Unresectable Liver Cancer. - Intraoperative Magnetic Resonance Imaging for Radiofrequency Ablation of Hepatic Tumors. - Surgically Unresectable and Chemotherapy-Refractory Metastatic Liver Carcinoma: Treatment with Yttrium-90 Microsphere Followed by Assessment with Positron Emission Tomography. - Unresectable Liver Metastases from Colorectal Cancer: Methodology and Prognosis with Radiofrequency Ablation. - Hepatocellular Carcinoma. - Screening with Ultrasonography of Patients at High-Risk for Hepatocellular Carcinoma: Thrombocytopenia as a Valid Surrogate of Cirrhosis. - Hepatocellular Carcinoma: Contrast-Enhanced Sonography. - Focal Liver Lesion: Nonlinear Contrast-Enhanced Ultrasound Imaging. - Hepatocellular Carcinoma: Magnetic Resonance Imaging. - Expression of Vascular Endothelial Growth Factor in Hepatocellular Carcinoma: Correlation with Radiologic Findings. - Detection of Small Hepatic Lesions: Superparamagnetic Oxide-Enhanced Diffusion-Weighted T2 FSE Imaging. - Diagnosis of Hepatocellular Carcinoma: Multidetector-Row Computed Tomography and Magnetic Resonance Imaging. - Hepatocellular Carcinoma: Effect of Injection Rate/Injection Duration of Contrast Material on Computed Tomography. - Detection of Combined Hepatocellular and Cholangiocarcinomas: Enhanced Computed Tomography. - Hepatocellular Carcinoma and Adenomatous Hyperplasia (Dysplastic Nodules): Dynamic Computed Tomography and a Combination of Computed Tomography and Angiography. - Hepatocellular Cancer in Cirrhotic Patients: Radiological Imaging. - Treatment of Hepatocellular Carcinoma with Thalidomide: Assessment with Power Doppler Ultrasound. - Perfusion Scintigraphy with Integrated Single Photon Emission Computed Tomography/Computed Tomography in the Management of Transarterial Treatment of Hepatic Malignancies. - Postoperative Interferon Alpha Treatment of Patients with Hepatocellular Carcinoma: Expression of p48 Using Tissue Microarray. - Hepatocellular Carcinoma: Overexpression of Homeoprotein Six1 as a Marker for Predicting Survival. - Hepatocellular Carcinoma: KiSS-1 Overexpression as a Prognostic Factor. - Hepatocellular Carcinoma: Prognosis Using Hepatoma-Derived Growth Factor Immunohistochemistry. - Hepatitis C Virus-Related Human Hepatocellular Carcinoma: Predictive Markers Using Proteomic Analysis (Methodology). - Metastases. - Liver Metastases from Colorectal Cancer: Ultrasound Imaging. - Preclinical Liver Metastases: Three-Dimensional High-Frequency Ultrasound Imaging. - Colorectal Liver Metastases: 18F-Fluorodeoxyglucose-Positron Emission Tomography. - Biliary Cancer. - Biliary Cystic Tumors: Clinicopathological Features. - Cholangiocarcinoma: Intraductal Sonography. - Extrahepatic Bile Duct Carcinoma: Role of the p53 Protein Family. - Extrahepatic Bile Duct Carcinoma: Mucin 4, a Poor Prognostic Factor. - Hilar Cholangiocarcinoma: Photodynamic Therapy and Stenting. - Splenic Cancer. - Splenic Metastases: Diagnostic Methods.
